FAKTOR OPTIONSSCHEIN - ELI LILLY & CO | Market Closed - Deutsche Boerse AG 18:35:09 31/05/2024 BST | ||
| 3.42 EUR | +1.48% |
|
| 1 month | -16.59% | ||
| 3 months | -29.34% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 31/05/24 | 3.42 | +1.48% |
| 30/05/24 | 3.37 | -3.99% |
| 29/05/24 | 3.51 | -0.85% |
| 28/05/24 | 3.54 | +4.42% |
| 27/05/24 | 3.39 | -2.59% |
Delayed Quote Deutsche Boerse AG
Last update May 31, 2024 at 06:35 pm
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | UBS |
| WKN | UM2B2J |
| ISIN | DE000UM2B2J1 |
| Date issued | 16/02/2024 |
| Strike | 1,087 $ |
| Maturity | Unlimited |
| Parity | 72.8 : 1 |
| Emission price | 4.88 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 5.28 € |
|---|---|
| Lowest since issue | 3.32 € |
| Spread | 0.05 € |
| Spread % | 1.47% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
820.3
USD
Average target price
852.5
USD
Spread / Average Target
+3.92%
- Stock Market
- Certificates
- Certificat
